NCT07750496RecruitingPhase 4
Outcomes After Planned Discontinuation of AntiSeizure Medication
Study Testing Outcomes After Planned Discontinuation of AntiSeizure Medication
Source: ClinicalTrials.gov · Last updated 6 Aug 2026
Brief summary (registry, in English)
The main purpose of this study is to understand the effects of continuing versus discontinuing antiseizure medications after a period of seizure-freedom. Physician guidelines endorse that after a period of seizure-freedom, the risk of another seizure may be low enough to allow patients to consider coming off antiseizure medication to see if they still need it. However, evidence is limited regarding how much continuing antiseizure medication still reduces seizures versus increases side effects after a patient has been treated for a while. This study will determine whether discontinuing antiseizure medications benefits patients.
- Status (registry)
- Recruiting
- Phase (registry)
- Phase 4
- Study type
- Interventional
- Enrollment
- 40 (estimated)
- First submitted
- 2 Aug 2026
- Start date
- Aug 2026
- Primary completion date
- Aug 2029
- Lead sponsor
- University of Michigan
- Diseases
- Epilepsy
- NCT number
- NCT07750496
What you commit to
- Study type: Interventional · Phase 4
- Planned participants: 40
- From Aug 2026 to the primary completion date, Aug 2029
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- History of epilepsy surgery
- Large space-occupying radiographic lesion such as a large cortical tumor, large artery stroke, or encephalomalacia from traumatic brain injury.
- Subject has any other clinically significant conditions or circumstances that in the judgment of the investigator or treating clinician should preclude study participation.
- Please note: The researchers will ask participants not to drive for 2 months after ASM discontinuation if on monotherapy, and exercise caution while driving if stopping one antiseizure medication but remaining on others
Other
- Current pregnancy or planned pregnancy during the study period
Who the study is looking for
- Provision of signed and dated informed consent form
- Stated willingness to comply with all study procedures and availability for the duration of the study
- Diagnosis of epilepsy
- At least 2 years since participants most recent seizure
- At most 35% calculated 1-year post-discontinuation seizure risk, based upon the existing multivariable calculator if they are on only 1 ASM, otherwise no such restriction if they are more than 1 ASM
- Willingness to adhere to the study intervention
- Taking at least 1 antiseizure medication prior to enrollment
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| University of Michigan Coordinator of this site? Confirm its status | Ann Arbor | United States | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.